The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price versions of the same drug ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.